To address these symptoms, secukinumab, an IL-17A inhibitor effective against both psoriasis and ankylosing spondylitis, was initiated with a loading dose of 150 mg weekly for 4 weeks, followed by monthly maintenance doses. This evidence concerns the gene IL17A and psoriasis.